首页> 美国卫生研究院文献>other >GENE EXPRESSION PROFILES AS MARKERS OF AGGRESSIVE DISEASE—EGFR AS A FACTOR
【2h】

GENE EXPRESSION PROFILES AS MARKERS OF AGGRESSIVE DISEASE—EGFR AS A FACTOR

机译:基因表达谱为进展性疾病的标志—EGFR为一个因素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We previously reported that 43 (58%) of 75 head and neck squamous cell carcinoma (HNSCC) tumors harbor increased epidermal growth factor receptor (EGFR) gene copy numbers as determined by fluorescent in situ hybridization. In this study, an increased EGFR copy number was associated with decreased progression-free survival and overall survival of HNSCC patients. However, activated EGFR protein levels are difficult to quantify by immunohistochemistry and are subject to dynamic regulation, specifically receptor downregulation on ligand binding. Therefore, we generated an activated EGFR gene expression signature in an in vitro HaCaT keratinocyte model system to further study genes involved in the EGFR signaling pathway in HNSCC. The results from this model system have suggested that the activated EGFR signature might reflect the activated state of the EGFR pathway in human HNSCC tumors and that it is associated with the increased EGFR gene copy number by fluorescent in situ hybridization. Furthermore, the activated EGFR signature has provided additional leads, because they are related to co-regulated molecular pathways and associated gene products on activation of EGFR. These could be exploited to refine and optimize combination therapies to be used in conjunction with available EGFR inhibitors in individual HNSCC patients.
机译:我们先前曾报道,通过荧光原位杂交测定,在75例头颈鳞状细胞癌(HNSCC)肿瘤中,有43例(58%)具有增加的表皮生长因子受体(EGFR)基因拷贝数。在这项研究中,EGFR拷贝数增加与HNSCC患者的无进展生存期降低和总体生存期降低有关。但是,活化的EGFR蛋白水平很难通过免疫组织化学定量,并且需要进行动态调节,尤其是受体对配体结合的下调。因此,我们在体外HaCaT角质形成细胞模型系统中产生了一个激活的EGFR基因表达签名,以进一步研究HNSCC中EGFR信号通路的基因。该模型系统的结果表明,激活的EGFR信号可能反映了人类HNSCC肿瘤中EGFR途径的激活状态,并且与通过荧光原位杂交增加的EGFR基因拷贝数有关。此外,激活的EGFR签名提供了额外的线索,因为它们与EGFR激活时共同调控的分子途径和相关的基因产物有关。这些可以被利用来改进和优化在单个HNSCC患者中与可用的EGFR抑制剂联合使用的联合疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号